Cargando…

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study

BACKGROUND: For patients with recurrent flares of gout, tophi, urate crystal arthropathy, and renal stones, urate-lowering therapies (ULTs, including allopurinol and febuxostat) are the first-line treatment. Due to the widespread use of these ULTs (especially in patients with impaired renal function...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rey, Amayelle, Batteux, Benjamin, Laville, Solène M., Marienne, Justine, Masmoudi, Kamel, Gras-Champel, Valérie, Liabeuf, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842268/ https://www.ncbi.nlm.nih.gov/pubmed/31703711 http://dx.doi.org/10.1186/s13075-019-2011-y

Ejemplares similares

Evaluation of Changes Over Time in the Drug Burden and Medication Regimen Complexity in ESRD Patients Before and After Renal Transplantation
por: Marienne, Justine, et al.
Publicado: (2020)

Risk factors for and characteristics of community‐ and hospital‐acquired drug‐induced acute kidney injuries
por: Rey, Amayelle, et al.
Publicado: (2022)

Early steroid withdrawal has a positive effect on bone in kidney transplant recipients: a propensity score study with inverse probability-of-treatment weighting
por: Batteux, Benjamin, et al.
Publicado: (2020)

Drugs associated with incident fragility fractures in kidney transplant recipients
por: Batteux, Benjamin, et al.
Publicado: (2022)

Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase(®))
por: Dernoncourt, Amandine, et al.
Publicado: (2022)

Use of the Capture-Recapture Method to Estimate the Frequency of Community- and Hospital-Acquired Drug-Induced Acute Kidney Injuries in French Databases
por: Rey, Amayelle, et al.
Publicado: (2022)

Association between Uremic Toxin Concentrations and Bone Mineral Density after Kidney Transplantation
por: Batteux, Benjamin, et al.
Publicado: (2020)

Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation
por: Gaucher, Louis, et al.
Publicado: (2021)

Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors
por: Gaucher, Louis, et al.
Publicado: (2021)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists
por: Liabeuf, Sophie, et al.
Publicado: (2015)

Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
por: Park, Seokwoo, et al.
Publicado: (2022)

Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists
por: Liabeuf, Sophie, et al.
Publicado: (2016)

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
por: Mitsuboshi, Satoru, et al.
Publicado: (2015)

Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice
por: Karve, Ashwini V., et al.
Publicado: (2013)

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients
por: Ziga-Smajic, Nermina, et al.
Publicado: (2020)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
por: Peng, Yueh-Lung, et al.
Publicado: (2020)

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
por: MacDonald, Thomas M, et al.
Publicado: (2014)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

Impact of the COVID-19 outbreak on the reporting of adverse drug reactions associated with self-medication
por: Gras, M., et al.
Publicado: (2021)

Comparison of efficacy and safety between febuxostat and allopurinol in early post‐renal transplant recipients with new onset of hyperuricemia
por: Shen, Xiaoju, et al.
Publicado: (2018)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review
por: Pluquet, Maxime, et al.
Publicado: (2022)

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database
por: Altan, Aylin, et al.
Publicado: (2015)

A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
por: Pichholiya, Meenu, et al.
Publicado: (2016)

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
por: Kim, Sollip, et al.
Publicado: (2017)

Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin
por: Lehtisalo, Minna, et al.
Publicado: (2020)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
por: Dewi, Christiyanti, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3eadm7j6fc8kkcf5aea8djmkkg